Journal
PHARMACOGENETICS AND GENOMICS
Volume 23, Issue 11, Pages 636-642Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/FPC.0b013e3283655091
Keywords
epidermal growth factor receptor; erlotinib; gefitinib; pharmacogenomics; tyrosine kinase inhibitor
Funding
- National Institutes of Health/National Institute of General Medical Sciences [R24 GM61374]